A federal judge in Pennsylvania today denied SmithKline Beecham Corp., doing business as GlaxoSmithKline (GSK), a second ch ...

For the third time in almost as many months, a federal judge has found that a plaintiff’s failure-to-warn claim against the maker of a selective serotonin reuptake ...

My days of predicting outcomes in antidepressant cases are over thanks to the Third Circuit’s ruling in Colacicco . That decision was a bitter pill (no pun intended ...

While watching the U.S. House of Representatives’ Committee on Oversight and Government Reform’s hearing today on drug preemption, the first thing that struck me wa ...

That’s hot!

Two rulings within the past 24 hours should have attorneys representing prescription drug makers popping open something cold whether it be some champagne or a cola-cicco. Create an account or login to post comments. | Comments (0)

A federal judge in California on Jan. 31 awarded summary judgment to SmithKline Beecham Corp., doing business as GlaxoSmithKline (GSK), in a case involving the February 1997  death of a 13-year-old boy who died as a  result of injuries h ...

A federal judge in Oklahoma on Jan. 17 granted a motion for partial summary judgment filed by Wyeth in which the company argued that a widow's state law failure-to-warn claims are preempted by Food and Drug Administration regulations.

The past two weeks have featured medical device preemption arguments before the Supreme Court and drug preemption arguments before the Third Circuit, both ably covered by my colleagues Dylan McGuire and Shane Dilworth. And although both touch on the im ...

The hotly contested topic of Medical Device preemption came before the Supreme Court last week in the case Charles R. Riegel, et al. v. Medtronic, Inc. (No. 06-179, U.S. Sup.). I attended the hearing and watched Public Citizen attorney Alliso ...